Back to search results

Elevated Rate Pacing for Cardiac Amyloidosis

This study is looking at how adjusting your pacemaker settings might improve symptoms for people with cardiac amyloidosis (a condition where abnormal proteins build up in the heart). If you have cardiac amyloidosis and an implanted pacemaker, you might be able to join. The study will involve giving participants a personalized pacemaker setting based on their height and heart function. Researchers will measure improvements in heart failure symptoms and overall well-being using a questionnaire, and track any heart-related events over four months. The study aims to enroll 10 adult participants, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 10 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will receive a personalized pacing protocol. Outcomes will be measured at Month 4.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for four months after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07583823

Elevated Rate Pacing of Cardiac Amyloidosis

Recruiting
NAAges 18+InterventionalSupportive care
University of Minnesota
~10 participants
Updated 2026-05-13 on ClinicalTrials.gov
What's tested:Pacemaker Rate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Kansas City Cardiomyopathy Questionnaire Score
Measured over Month 4
+1 more outcome measured

Conditions

Cardiac Amyloidosis
Pacemaker

Explore related trials

Cardiac Amyloidosis

NCT07583823

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Minnesota

    Minneapolis, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Valmiki Maharaj · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Meghan Muscala
[email protected]
612-626-5863
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults 18 and older
Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
Implanted Cardiac Pacemaker (+/- Defibrillator)
Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
Non-dilated left ventricle by echocardiography
Ability to provide written consent
English Speaking

Exclusion

Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony)
Dilated left ventricle

What this trial measures

  • Kansas City Cardiomyopathy Questionnaire ScoreMonth 4

    75-100 representing good to excellent health, and 0-24 representing very poor to poor health

  • Composite of any cardiovascular eventMonth 4

    admission or urgent visit for heart failure and atrial fibrillation, myocardial infarction or stroke